Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial)
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2022-06-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/12/6/e060431.full |
| _version_ | 1811245248674791424 |
|---|---|
| author | Joachim G J V Aerts Sjoerd H van der Burg Martijn P Lolkema Sai Ping Lau Freek R van ’t Land Marjolein Y V Homs Casper H J van Eijck |
| author_facet | Joachim G J V Aerts Sjoerd H van der Burg Martijn P Lolkema Sai Ping Lau Freek R van ’t Land Marjolein Y V Homs Casper H J van Eijck |
| author_sort | Joachim G J V Aerts |
| collection | DOAJ |
| first_indexed | 2024-04-12T14:37:03Z |
| format | Article |
| id | doaj.art-40029583d6574b97bc53298a9b94c429 |
| institution | Directory Open Access Journal |
| issn | 2044-6055 |
| language | English |
| last_indexed | 2024-04-12T14:37:03Z |
| publishDate | 2022-06-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj.art-40029583d6574b97bc53298a9b94c4292022-12-22T03:29:03ZengBMJ Publishing GroupBMJ Open2044-60552022-06-0112610.1136/bmjopen-2021-060431Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial)Joachim G J V Aerts0Sjoerd H van der Burg1Martijn P Lolkema2Sai Ping Lau3Freek R van ’t Land4Marjolein Y V Homs5Casper H J van Eijck6Pulmonary Medicine, Erasmus MC Kanker Instituut, Rotterdam, The NetherlandsDepartment of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The NetherlandsDepartment of Medical Oncology, Erasmus Medical Center Cancer Center. Erasmus Medical Center, Rotterdam, The NetherlandsDepartment of Surgery, Erasmus MC, Rotterdam, The NetherlandsDepartment of Surgery, Erasmus MC, Rotterdam, The NetherlandsDepartment of Medical Oncology, Erasmus MC, Rotterdam, The NetherlandsDepartment of Surgery, Erasmus MC, Rotterdam, The Netherlandshttps://bmjopen.bmj.com/content/12/6/e060431.full |
| spellingShingle | Joachim G J V Aerts Sjoerd H van der Burg Martijn P Lolkema Sai Ping Lau Freek R van ’t Land Marjolein Y V Homs Casper H J van Eijck Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial) BMJ Open |
| title | Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial) |
| title_full | Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial) |
| title_fullStr | Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial) |
| title_full_unstemmed | Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial) |
| title_short | Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial) |
| title_sort | safety and tumour specific immunological responses of combined dendritic cell vaccination and anti cd40 agonistic antibody treatment for patients with metastatic pancreatic cancer protocol for a phase i open label single arm dose escalation study reactive 2 trial |
| url | https://bmjopen.bmj.com/content/12/6/e060431.full |
| work_keys_str_mv | AT joachimgjvaerts safetyandtumourspecificimmunologicalresponsesofcombineddendriticcellvaccinationandanticd40agonisticantibodytreatmentforpatientswithmetastaticpancreaticcancerprotocolforaphaseiopenlabelsinglearmdoseescalationstudyreactive2trial AT sjoerdhvanderburg safetyandtumourspecificimmunologicalresponsesofcombineddendriticcellvaccinationandanticd40agonisticantibodytreatmentforpatientswithmetastaticpancreaticcancerprotocolforaphaseiopenlabelsinglearmdoseescalationstudyreactive2trial AT martijnplolkema safetyandtumourspecificimmunologicalresponsesofcombineddendriticcellvaccinationandanticd40agonisticantibodytreatmentforpatientswithmetastaticpancreaticcancerprotocolforaphaseiopenlabelsinglearmdoseescalationstudyreactive2trial AT saipinglau safetyandtumourspecificimmunologicalresponsesofcombineddendriticcellvaccinationandanticd40agonisticantibodytreatmentforpatientswithmetastaticpancreaticcancerprotocolforaphaseiopenlabelsinglearmdoseescalationstudyreactive2trial AT freekrvantland safetyandtumourspecificimmunologicalresponsesofcombineddendriticcellvaccinationandanticd40agonisticantibodytreatmentforpatientswithmetastaticpancreaticcancerprotocolforaphaseiopenlabelsinglearmdoseescalationstudyreactive2trial AT marjoleinyvhoms safetyandtumourspecificimmunologicalresponsesofcombineddendriticcellvaccinationandanticd40agonisticantibodytreatmentforpatientswithmetastaticpancreaticcancerprotocolforaphaseiopenlabelsinglearmdoseescalationstudyreactive2trial AT casperhjvaneijck safetyandtumourspecificimmunologicalresponsesofcombineddendriticcellvaccinationandanticd40agonisticantibodytreatmentforpatientswithmetastaticpancreaticcancerprotocolforaphaseiopenlabelsinglearmdoseescalationstudyreactive2trial |